Real-world evidence on first-and second-line palliative chemotherapy in advanced pancreatic cancer  

作　　者：Hakon Blomstrand Atul Batra Winson Y Cheung Nils Oskar Elander 

机构地区：[1]Department of Biomedical and Clinical Sciences,Linköping University,Linköping 58185,Sweden [2]Department of Medical Oncology,All India Institute of Medical Sciences,New Delhi 110029,India [3]Department of Oncology,University of Calgary,Calgary T2N 4N1,Canada

出　　处：《World Journal of Clinical Oncology》2021年第9期787-799,共13页世界临床肿瘤学杂志（英文版）

摘　　要：In spite of recent diagnostic and therapeutic advances,the prognosis of pancreatic ductal adenocarcinoma(PDAC)remains very poor.As most patients are not amenable to curative intent treatments,optimized palliative management is highly needed.One key question is to what extent promising results produced by randomized controlled trials(RCTs)correspond to clinically meaningful outcomes in patients treated outside the strict frames of a clinical trial.To answer such questions,real-world evidence is necessary.The present paper reviews and discusses the current literature on first-and second-line palliative chemotherapy in PDAC.Notably,a growing number of studies report that the outcomes of the two predominant first-line multidrug regimens,i.e.gemcitabine plus nabpaclitaxel(GnP)and folfirinox(FFX),is similar in RCTs and real-life populations.Outcomes of second-line therapy following failure of first-line regimens are still dismal,and considerable uncertainty of the optimal management remains.Additional RCTs and real-world evidence studies focusing on the optimal treatment sequence,such as FFX followed by GnP or vice versa,are urgently needed.Finally,the review highlights the need for prognostic and predictive biomarkers to inform clinical decision making and enable personalized management in advanced PDAC.

关 键 词：Pancreatic cancer Palliative therapy Cancer chemotherapy GEMCITABINE Paclitaxel nano albumin-bound Folfirinox 

分 类 号：R735.9[医药卫生—肿瘤]